Pertuzumab biosimilar is under clinical development by EirGenix and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer). According to GlobalData, Phase I drugs for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Pertuzumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pertuzumab biosimilar overview
Pertuzumab biosimilar is under development for the treatment of early breast cancer, metastatic breast cancer, human epidermal growth factor receptor 2 positive breast cancer. It is formulated as a solution and administered through intravenous route. It acts by targeting extracellular dimerization domain of human epidermal growth factor receptor 2 (HER2).
EirGenix is a Taiwan-based company primarily engaged in the development of antibody drugs and the manufacture of biopharmaceuticals. Its main businesses include the provision of Contract Development & Manufacturing Organization (CDMO) services. It is
For a complete picture of Pertuzumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.